

NICOTINE inhaler (Voke®) for nicotine dependence

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of NICOTINE inhaler (Voke®) for nicotine dependence.

GREY

Voke® is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. It relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence.¹

Voke® is indicated in pregnant and lactating women making a quit attempt.¹

> This recommendation will be reviewed within 6 months by the Formulary and Guidelines Subgroup.

In the meantime, clinicians should continue to follow local and national guidance and prescribe local formulary choices for the treatment of nicotine dependence for patients who are not under the care of local Stop Smoking services:

- NICE Pathway Stop smoking interventions and services, last updated 12 December 2019
- > Pan Mersey APC Formulary Nicotine dependence

References

1. Kind Consumer Ltd. Summary of Product Characteristics; Voke 0.45 mg Inhaler, 31 May 2019. Accessed online 17 December 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

Date of issue: 19 Dec 2019 Prescribing policy statement

Review date: Dec 2021 (or earlier if there is significant new evidence relating to this recommendation) APC administration provided by <u>Midlands and Lancashire Commissioning Support Unit</u>

Version: 1.0